The history of the cholinergic hypothesis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Behavioural Brain Research

• Publication date

  2011-08-10

• Fields of study

  Medicine, Psychology, History

• Identifiers
  DOI 10.1016/j.bbr.2009.12.044PMID 20060018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Looking at neurotransmitters in the microscope.

  2010cited by this paper
• Genetics of Alzheimer's disease: recent advances

  2009cited by this paper
• Chronic Dietary Administration of Valproic Acid Protects Neurons of the Rat Nucleus Basalis Magnocellularis from Ibotenic Acid Neurotoxicity

  2009cited by this paper
• Cell Cycle Elongation Impairs Proliferation of Cerebellar Granule Cell Precursors in the Ts65Dn Mouse, an Animal Model for Down Syndrome

  2009cited by this paper
• Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence.

  2008cited by this paper
• The Place of Choline Acetyltransferase Activity Measurement in the “Cholinergic Hypothesis” of Neurodegenerative Diseases

  2008cited by this paper
• Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.

  2008cited by this paper
• Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

  2007cited by this paper
• Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice

  2007cited by this paper
• Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials

  2007cited by this paper
• Towards a muscarinic hypothesis of schizophrenia

  2007cited by this paper
• Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.

  2007cited by this paper
• Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

  2007cited by this paper
• Ispronicline (Targacept).

  2006cited by this paper
• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases

  2006cited by this paper
• Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.

  2006cited by this paper
• Paradoxical (REM) sleep genesis: the switch from an aminergic-cholinergic to a GABAergic-glutamatergic hypothesis.

  2006cited by this paper
• Cholinesterase Inhibitors in the Clinical Management of Alzheimer's Disease: Importance of Early and Persistent Treatment

  2006cited by this paper
• The cholinergic system in Down's syndrome

  2006cited by this paper
• The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease.

  2005cited by this paper
• Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice.

  2005cited by this paper
• Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level

  2005cited by this paper
• Über humorale übertragbarkeit der Herznervenwirkung

  2005cited by this paper
• Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease.

  2004cited by this paper
• Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease

  2004cited by this paper
• [Down syndrome].

  2003cited by this paper
• The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury

  2003cited by this paper
• The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development

  2003cited by this paper
• Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory.

  2003cited by this paper
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction.

  2003cited by this paper
• Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology

  2003cited by this paper
• Cholinergic neuropathology in a mouse model of Alzheimer's disease

  2003cited by this paper
• Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease

  2002cited by this paper
• Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment

  2002influential reference
• Mild cognitive impairment and the cholinergic hypothesis: A very different take on recent data

  2002cited by this paper
• Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes.

  2002cited by this paper
• Animal Model Stable -Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice

  2002cited by this paper
• Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of anti‐nerve‐growth‐factor mice

  2002cited by this paper
• The cholinergic pathology in Alzheimer's disease – discrepancies between clinical experience and pathophysiological findings

  2002cited by this paper
• Beyond the usual suspects: a cholinergic route for panic attacks

  2002cited by this paper
• Topography of neurochemical alterations in the CNS of aged rats

  2001cited by this paper
• Down‐regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease

  2001cited by this paper
• Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?

  2001cited by this paper
• Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment

  2001cited by this paper
• Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion

  2001cited by this paper
• Nerve growth factor signaling, neuroprotection, and neural repair.

  2001cited by this paper
• Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes

  2001cited by this paper
• Atomically defined mechanism for proton transfer to a buried redox centre in a protein

  2000cited by this paper
• A learning de ® cit related to age and b-amyloid plaques in a mouse model of Alzheimer ' s disease

  2000cited by this paper
• Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice.

  2000cited by this paper
• Single and multiple transgenic mice as models for Alzheimer's disease.

  2000cited by this paper
• Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss.

  2000cited by this paper
• Phenotypic Knockout of Nerve Growth Factor in Adult Transgenic Mice Reveals Severe Deficits in Basal Forebrain Cholinergic Neurons, Cell Death in the Spleen, and Skeletal Muscle Dystrophy

  2000cited by this paper
• Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome.

  2000cited by this paper
• Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients.

  2000cited by this paper
• On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

  2000cited by this paper
• Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease

  2000cited by this paper
• The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease

  2000cited by this paper
• Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease

  1999cited by this paper
• Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy.

  1999cited by this paper
• Cholinergic markers in elderly patients with early signs of Alzheimer disease.

  1999cited by this paper
• Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases.

  1999cited by this paper
• Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes

  1999cited by this paper
• Cortical Cholinergic Dysfunction After Human Head Injury

  1998cited by this paper
• Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use.

  1998cited by this paper
• Neuron loss in APP transgenic mice

  1998cited by this paper
• Does smoking protect from Alzheimer’s disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history

  1997cited by this paper
• Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins.

  1997cited by this paper
• Cholinergic activity and amyloid precursor protein metabolism.

  1997cited by this paper
• Vesicular acetylcholine transporter density and Alzheimer's disease.

  1997cited by this paper
• Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse

  1997cited by this paper
• Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease

  1996cited by this paper
• Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease.

  1996cited by this paper
• Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease

  1996cited by this paper
• Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease.

  1996cited by this paper
• From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease.

  1996cited by this paper
• Preliminary characterization of the central nervous system in partial trisomy 16 mice.

  1995cited by this paper
• Ageing: the cholinergic hypothesis of cognitive decline.

  1995cited by this paper
• Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease.

  1995cited by this paper
• Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis

  1995cited by this paper
• Cholinesterase Inhibitors in Alzheimer's Disease

  1994cited by this paper
• Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome).

  1994cited by this paper
• Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats

  1994cited by this paper
• NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients.

  1994cited by this paper
• Down syndrome.

  1993cited by this paper
• Basal forebrain neurons and memory: a biochemical, histological, and behavioral study of differential vulnerability to ibotenate and quisqualate.

  1992cited by this paper
• Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.

  1992cited by this paper
• Monoaminergic and cholinergic synaptic markers in the nucleus basalis of meynert (nbM): Normal age‐related changes and the effect of heart disease and Alzheimer's disease

  1992cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper
• Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia

  1992cited by this paper
• Excitotoxic lesions of rat basal forebrain: differential effects on choline acetyltransferase in the cortex and amygdala.

  1992cited by this paper
• Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor.

  1991cited by this paper
• Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence.

  1991cited by this paper
• The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions.

  1991cited by this paper
• Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease.

  1991cited by this paper
• Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease.

  1991cited by this paper
• Amyloid deposition as the central event in the aetiology of Alzheimer's disease.

  1991cited by this paper
• Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome.

  1990cited by this paper

• Schiff Base Complex rescues mice against scopolamine-induced cognitive dysfunction.

  2026cites this paper
• Synthesis of Anti‐Alzheimer Molecules: Bridging Chemical Approaches to Pharmaceuticals

  2025cites this paper
• Integrated insight and in silico investigation of hybrid bis-thiazolidinone derivatives along with anti-Alzheimer activity

  2025cites this paper
• Chemical Composition, Antioxidant, Acetylcholinesterase and β-Lactamase Inhibitory Activities of Essential Oils from Clerodendrum cyrtophyllum Turcz. and Clerodendrum fortunatum L.

  2025cites this paper
• Pleiotropic prodrugs for both symptomatic and disease-modifying treatment of Alzheimer’s disease

  2025cites this paper
• Gallic acid enhances memory, learning and reduces neuroinflammation in a rat model of scopolamine-induced cholinergic dysfunction

  2025cites this paper
• Fast-response NIR "off-on" fluorescent sensor for hepaticinjury visualization through butyrylcholinesterase expression monitoring.

  2025cites this paper
• Benzorhodol derived far-red/near-infrared fluorescent probes for selective and sensitive detection of butyrylcholinesterase activity in living cells and the non-alcoholic fatty liver of zebrafish.

  2024cites this paper
• Tests of abnormal gaze behavior increase the accuracy of mild cognitive impairment assessments

  2024cites this paper
• Insight into role of triazole derived Schiff base bearing sulfonamide derivatives in targeting Alzheimer's disease: Synthesis, characterization, in vitro and in silico assessment

  2024cites this paper
• Therapeutic potential of clinically proven natural products in the management of dementia

  2024cites this paper
• Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?

  2024cites this paper
• Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics

  2024cites this paper
• Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation.

  2024cites this paper
• Quinazolinone-Hydrazine Cyanoacetamide Hybrids as Potent Multitarget-Directed Druggable Therapeutics against Alzheimer's Disease: Design, Synthesis, and Biochemical, In Silico, and Mechanistic Analyses.

  2024cites this paper
• Novel 1,2,4‐triazole derivatives containing the naphthalene moiety as selective butyrylcholinesterase inhibitors: Design, synthesis, and biological evaluation

  2024cites this paper
• Research Progress of Chemical Synthesis Drugs and Biotechnology Drugs for Alzheimer’s Disease

  2024cites this paper
• Synthesis and evaluation of a highly selective cannabidiol amide cholinesterase inhibitor

  2024cites this paper
• Molecular Modeling Insights on the Pharmaceuticals and Hypotheses of Alzheimer's Disease.

  2024cites this paper
• Novel hybrid structures based on 4-Chlorobenzenesulfonyl and 1,2,3-triazoles: Synthesis, in vitro biological activities and in silico studies

  2024cites this paper
• A review of chitosan polysaccharides: Neuropharmacological implications and tissue regeneration.

  2024cites this paper
• Obsessive compulsive symptoms, mild neurocognitive disorder and dementia: A systematic review

  2024cites this paper
• Recent progress towards the development of fluorescent probes for the detection of disease-related enzymes.

  2024cites this paper
• Nanomodulators That Target Alzheimer’s Disease: A Review

  2024cites this paper
• Evaluation of the biological efficiency of Terminalia chebula fruit extract against neurochemical changes induced in brain of diabetic rats: an epigenetic study

  2024cites this paper
• Exploring butyrylcholinesterase expression in diseases using a promising fluorescent imaging tool

  2023cites this paper
• New cyclopentaquinoline and 3,5-dichlorobenzoic acid hybrids with neuroprotection against oxidative stress for the treatment of Alzheimer’s disease

  2023cites this paper
• Ex Vivo Electrochemical Monitoring of Cholinergic Signaling in the Mouse Colon Using an Enzyme-Based Biosensor.

  2023cites this paper
• Potentiality Assessment of the Acetylcholinesterase-Inhibitory Activity of Olive Oil with an Additive Edible Insect Powder

  2023cites this paper
• Evaluation of 4-aminoquinoline derivatives with an n-octylamino spacer as potential multi-targeting ligands for the treatment of Alzheimer's disease.

  2023cites this paper
• Structural Degeneration of the Nucleus basalis of Meynert in Mild Cognitive Impairment and Alzheimer’s Disease – Evidence from an MRI-based Meta-Analysis

  2023cites this paper
• Is creatine a CNS neurotransmitter?

  2023cites this paper
• New Advances in the Exploration of Esterases with PET and Fluorescent Probes

  2023cites this paper
• The Neurobiology and Therapeutic Potential of Multi-Targeting β-secretase, Glycogen Synthase Kinase 3β and Acetylcholinesterase in Alzheimer's Disease.

  2023cites this paper
• Synthesis and biological evaluation of novel zinc (II) and nickel (II) phthalocyanines as cholinesterase inhibitors

  2023cites this paper
• Dual-Mode Ratiometric Electrochemical and Turn-On Fluorescent Detection of Butyrylcholinesterase Utilizing a Single Probe for the Diagnosis of Alzheimer's Disease.

  2023cites this paper
• Exploring the Multitarget Activity of Wedelolactone against Alzheimer’s Disease: Insights from In Silico Study

  2023cites this paper
• Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.

  2023cites this paper
• Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing.

  2023cites this paper
• Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer’s Disease

  2023cites this paper
• Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease

  2023cites this paper
• The Lipid Invasion Model: Growing Evidence for This New Explanation of Alzheimer’s Disease

  2023cites this paper
• Whole Person Modeling: a transdisciplinary approach to mental health research

  2023cites this paper
• Applications of Carbon Dots for the Treatment of Alzheimer’s Disease

  2022cites this paper
• Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybrids.

  2022cites this paper
• Discovery of pyrrole derivatives as acetylcholinesterase-sparing butyrylcholinesterase inhibitor

  2022cites this paper
• Synthesis, structural characterization and in vitro pharmacological properties of betanin-encapsulated chitosan nanoparticles.

  2022cites this paper
• Perfluorinated chemicals (PFOA) can, by interacting with highly brominated diphenyl ethers (PBDE 209) during a defined period of neonatal brain development, exacerbate neurobehavioural defects.

  2022cites this paper
• Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease.

  2022cites this paper
• Synthesis, single crystal characterization and anti-AD activities of a novel complex of Cu(II) with in situ formed protonated chrysin derivative ligand.

  2022cites this paper
• Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice

  2022cites this paper
• Pharmacophore based virtual screening of cholinesterase inhibitors: search of new potential drug candidates as antialzheimer agents

  2022cites this paper
• Synthesis, Biological Evaluation and Machine Learning Prediction Model for Fluorinated Cinchona Alkaloid-Based Derivatives as Cholinesterase Inhibitors

  2022cites this paper
• It’s Groundhog Day! What Can the History of Science Say About the Crisis in Alzheimer’s Disease Research?

  2022cites this paper
• Asetilkolinesteraz ve Bütirilkolinesteraz Enzimlerinin Alzheimer Hastalığı ile İlişkisi

  2022cites this paper
• New Possibilities in the Therapeutic Approach to Alzheimer’s Disease

  2022cites this paper
• Novel Bisamide Alkaloids Enantiomers from Pepper Roots (Piper nigrum L.) with Acetylcholinesterase Inhibitory and Anti-Neuroinflammatory Effects.

  2022cites this paper
• Fluorosulfate-containing pyrazole heterocycles as selective BuChE inhibitors: structure-activity relationship and biological evaluation for the treatment of Alzheimer’s disease

  2022cites this paper
• Synthesis and Cholinesterase Inhibitory Potentials of (5-formylfuran-2-yl) methyl 3,4-dimethoxy/nitro benzoates

  2022cites this paper
• Near-Infrared Fluorescence Probe for Specific Detection of Acetylcholinesterase and Imaging in Live Cells and Zebrafish.

  2022cites this paper
• Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer’s Drug Galantamine

  2022cites this paper
• Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine as Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease

  2022cites this paper
• Real-Time Fluorescent Determination and Biological Imaging in Living Models via a Butyrylcholinesterase-Activated Fluorescent Probe

  2022cites this paper
• Downregulation of aromatase by siRNA decreases acetylcholinesterase mRNA and specific activity in SHSY5Y cells

  2022cites this paper
• Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)

  2022cites this paper
• A New Series of Aryloxyacetic Acids Endowed with Multi-Target Activity towards Peroxisome Proliferator-Activated Receptors (PPARs), Fatty Acid Amide Hydrolase (FAAH), and Acetylcholinesterase (AChE)

  2022cites this paper
• Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders

  2022cites this paper
• A Comparative Evaluation of the Total Cost of Ownership between Electric Two-Wheelers and Motorized Two-Wheelers from an Indian Perspective

  2022cites this paper
• Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review.

  2022cites this paper
• Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer's disease.

  2022cites this paper
• A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model

  2022cites this paper
• A gliclazide complex based on palladium towards Alzheimer's disease: promising protective activity against Aβ-induced toxicity in C. elegans.

  2022cites this paper
• New 1,2,3-Triazole-genipin Analogues and Their Anti-Alzheimer’s Activity

  2022cites this paper
• Recent Developments of Coumarin-based Hybrids in Drug Discovery.

  2022cites this paper
• New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators

  2021cites this paper
• Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease

  2021cites this paper
• The Mechanism by Which LiCl Attenuates the Impaired Ability of Learning and Memory of APP/PS1 Double Transgenic Mice May Involve Elevating the Expression of a7 Nicotinic Acetylcholine Receptors via Regulation of the Wnt/β-catenin Pathway

  2021cites this paper
• Intranasal galantamine/chitosan complex nanoparticles elicit neuroprotection potentials in rat brains via antioxidant effect

  2021cites this paper
• Cholinergic neurodegeneration in Alzheimer disease mouse models.

  2021cites this paper
• Structural Fractal Analysis of the Active Site of Acetylcholinesterase in Complexes with Huperzine A, Galantamine, and Donepezil

  2021cites this paper
• Binding studies of known molecules with acetylcholinesterase and bovine serum albumin: A comparative view.

  2021cites this paper
• Huprine Y - tryptophan heterodimers with potential implication to Alzheimer's disease treatment.

  2021cites this paper
• SIGNIFICANCE OF AROMATIC AMINO ACIDS IN STABILIZATION OF DIPLACONE AND HUMAN ACETYLCHOLINESTERASE COMPLEX

  2021cites this paper
• Structure–activity relationship, in vitro and in vivo evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease

  2021cites this paper
• RETRACTED ARTICLE: nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse

  2021cites this paper
• Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters.

  2021cites this paper
• The cannabinoid system and microglia in health and disease.

  2021cites this paper
• A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.

  2021cites this paper
• Alzheimer's Disease: Pathogenesis and Therapeutic interventions.

  2021cites this paper
• Design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases: Molecular dynamic, in vitro and in vivo studies.

  2021cites this paper
• Synthesis, characterization and pharmacological evaluation of quinoline derivatives and their complexes with copper(ΙΙ) in in vitro cell models of Alzheimer's disease.

  2021cites this paper
• Neuroinflammation in Alzheimer's disease and beneficial action of luteolin

  2021influential citation
• Quinuclidine-Based Carbamates as Potential CNS Active Compounds

  2021cites this paper
• Recent developments of synthesis and biological activity of sultone scaffolds in medicinal chemistry

  2021cites this paper
• Tadalafil Reversed H-89 – and Scopolamine – Induced Spatial Learning Impairments in Male Rats

  2021cites this paper
• Discovery of Natural Inhibitors of Cholinesterases from Hydrangea: In Vitro and In Silico Approaches

  2021cites this paper
• Multitarget Biological Profiling of New Naphthoquinone and Anthraquinone-Based Derivatives for the Treatment of Alzheimer’s Disease

  2021cites this paper
• Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)

  2021cites this paper
• Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.

  2021cites this paper
• Bioactive constituents from Thunbergia erecta as potential anticholinesterase and anti-ageing agents: Experimental and in silico studies.

  2021cites this paper